Results for
"[search-keyword]"
Sponsor content
50 result(s) found, displaying 1 to 10
-
Nov-2024Prescription medicine evaluationActive ingredient: cabozantinib (S)-malate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RELFYDESS relabotulinumtoxinA 100 units/mL solution for injection vial.
-
Australian Public Assessment Report (AusPAR)SOHONOS (palovarotene) has been approved to treat heterotopic ossification in individuals with fibrodysplasia ossificans progressiva.
-
Prescription medicine decision summaryRelfydess (relabotulinumtoxinA, purified Botulinum toxin type A) has been approved for the temporary improvement in the appearance of glabellar lines ("frown lines") and lateral canthal lines ("crows feet").
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 2.5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 1.5 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 1 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOHONOS palovarotene 10 mg capsule blister pack.
-
Cancellation by sponsorRequested by Ipsen Pty Ltd
Pages
- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Next page Next ›
- Last page Last »